MA33952B1 - Nouveau dérivé 3 -hydroxy- 5-arylisothiazole - Google Patents

Nouveau dérivé 3 -hydroxy- 5-arylisothiazole

Info

Publication number
MA33952B1
MA33952B1 MA35101A MA35101A MA33952B1 MA 33952 B1 MA33952 B1 MA 33952B1 MA 35101 A MA35101 A MA 35101A MA 35101 A MA35101 A MA 35101A MA 33952 B1 MA33952 B1 MA 33952B1
Authority
MA
Morocco
Prior art keywords
ring
arylisothiazole
hydroxy
derivative
new
Prior art date
Application number
MA35101A
Other languages
Arabic (ar)
English (en)
Inventor
Akihiro Okano
Naoto Kosuga
Munetaka Ohkouchi
Daido Hotta
Muneyoshi Makabe
Original Assignee
Mochida Pharmacal Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmacal Co Ltd filed Critical Mochida Pharmacal Co Ltd
Publication of MA33952B1 publication Critical patent/MA33952B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un activateur de gpr40 contenant comme principe actif un composé doté d'un nouvel effet agoniste de gpr40, son sel, ou un solvate de l'un ou de l'autre. L'invention concerne en particulier un sécrétagogue insulinique, et un agent prophylactique et/ou thérapeutique contre le diabète et l'obésité, etc., ledit composé étant représenté par la formule (i) (où n vaut 0 à 2, p vaut 0 à 4, j vaut 0 à 3, k vaut 0 à 2 ; le cycle a est un groupe aryle ou un groupe hétérocyclique facultativement substitué par l ; le cycle b est un cycle benzénique, un cycle pyridinique, ou un cycle pyrimidinique ; x est o, s, ou -nr7- ; r1 à r7 et l représentent un groupe spécifique).
MA35101A 2009-12-25 2010-12-24 Nouveau dérivé 3 -hydroxy- 5-arylisothiazole MA33952B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009295855 2009-12-25
JP2010043420 2010-02-26
PCT/JP2010/073464 WO2011078371A1 (fr) 2009-12-25 2010-12-24 Nouveau dérivé 3-hydroxy-5-arylisothiazole

Publications (1)

Publication Number Publication Date
MA33952B1 true MA33952B1 (fr) 2013-01-02

Family

ID=44195895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35101A MA33952B1 (fr) 2009-12-25 2010-12-24 Nouveau dérivé 3 -hydroxy- 5-arylisothiazole

Country Status (26)

Country Link
US (1) US8476287B2 (fr)
EP (1) EP2518060A4 (fr)
JP (2) JP5002077B2 (fr)
KR (1) KR20130004262A (fr)
CN (2) CN102712610B (fr)
AU (1) AU2010336225A1 (fr)
BR (1) BR112012015612A2 (fr)
CA (1) CA2785674A1 (fr)
CL (1) CL2012001722A1 (fr)
CO (1) CO6650337A2 (fr)
CR (1) CR20120345A (fr)
EA (1) EA201290574A1 (fr)
EC (1) ECSP12012056A (fr)
GT (1) GT201200217A (fr)
HN (1) HN2012001351A (fr)
IL (1) IL220616A0 (fr)
MA (1) MA33952B1 (fr)
MX (1) MX2012007474A (fr)
NI (1) NI201200113A (fr)
NZ (1) NZ601408A (fr)
PE (1) PE20121639A1 (fr)
PH (1) PH12012501456A1 (fr)
RU (1) RU2567755C2 (fr)
SG (1) SG181961A1 (fr)
WO (1) WO2011078371A1 (fr)
ZA (1) ZA201203416B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779398A1 (fr) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Nouveau derive de 3-hydroxy-5-arylisoxazole
AU2010336225A1 (en) 2009-12-25 2012-08-16 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
US8581584B2 (en) * 2010-05-26 2013-11-12 Florida State University Research Foundation Membrane proteins, mechanisms of action and uses thereof
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
EP2677869B1 (fr) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
AU2012248629A1 (en) * 2011-04-27 2013-11-28 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013154163A1 (fr) * 2012-04-11 2013-10-17 持田製薬株式会社 Nouveau dérivé de 5-aryl-1,2-thiazinane
CN106977495B (zh) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 Dna-pk抑制剂
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2880901A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composes tricycliques antidiabetiques
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
HRP20211855T1 (hr) 2013-03-12 2022-03-04 Vertex Pharmaceuticals Incorporated Inhibitori dnk-pk
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
PE20161022A1 (es) 2013-10-17 2016-11-12 Vertex Pharma Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn
HK1221465A1 (zh) 2013-11-14 2017-06-02 Cadila Healthcare Limited 新型杂环化合物
KR20170122782A (ko) * 2015-02-27 2017-11-06 난트바이오사이언스 인코포레이티드 키나아제 억제제로서의 피리미딘 유도체 및 그 치료적 용도
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2019204609A1 (fr) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Inhibiteurs pd-1/pd-l1
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN110066254B (zh) * 2018-11-16 2021-03-19 温州大学 一种异噻唑-3-酮化合物的制备方法
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4153589A4 (fr) 2020-05-19 2024-06-12 Kallyope, Inc. Activateurs d'ampk
EP4172162A4 (fr) 2020-06-26 2024-08-07 Kallyope, Inc. Activateurs d'ampk
CN115433143B (zh) * 2021-06-03 2023-10-13 中国科学院大连化学物理研究所 一种异噻唑啉酮类化合物的合成方法
CN115386028B (zh) * 2022-08-26 2023-06-23 长春理工大学 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法
WO2025140655A1 (fr) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Composés hétéroaryle utilisés en tant qu'inhibiteurs de protéine kinase multicibles

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562283A (en) 1968-07-01 1971-02-09 Rohm & Haas 1-oxo and 1,1-dioxo-3-isothiazolones
US3801575A (en) * 1972-01-24 1974-04-02 Rohm & Haas 3-hydroxyisothiazoles
WO1997031906A1 (fr) 1996-02-27 1997-09-04 Sankyo Company, Limited Derives d'isoxazole
CN1149204C (zh) 1999-01-13 2004-05-12 沃尼尔·朗伯公司 1-杂环取代的二芳基胺
JP2000204077A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
WO2004011446A1 (fr) 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Derives d'acide carboxylique d'indane, de dihydrobenzofurane et de tetrahydronaphthalene et leurs utilisations comme antidiabetiques
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CA2527691C (fr) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Compose cyclique condense
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2005051890A1 (fr) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Acides aminophenylcyclopropylcarboxyliques et leurs derives servant d'agonistes de gpr40
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
BRPI0615150A2 (pt) 2005-08-10 2017-06-20 Takeda Pharmaceuticals Co agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
CA2621949A1 (fr) 2005-09-14 2007-03-22 Amgen Inc. Acides propanoiques 3-substitues par un groupement 4-hydroxyphenyle a conformation contrainte pouvant etre employes dans le traitement de troubles metaboliques
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
EP2064193A1 (fr) 2006-09-07 2009-06-03 Amgen, Inc Modulateurs hétérocycliques du récepteur couplé à la protéine g (gpr40)
WO2008033931A1 (fr) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Acides carboxyliques de para-xylylène et isothiazolones utiles comme protéines tyrosine phosphatases (ptps) en particulier ptp-ib
JP5405120B2 (ja) 2006-12-01 2014-02-05 Ｍｓｄ株式会社 新規フェニル−イソキサゾール−３−オール誘導体
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
MY149648A (en) 2007-09-21 2013-09-30 Sanofi Aventis Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
MX2010004435A (es) 2007-10-26 2010-05-13 Japan Tobacco Inc Compuestos espiro y uso farmaceutico de los mismos.
AU2009220163B2 (en) 2008-03-06 2011-10-06 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
EP2298750A4 (fr) 2008-06-02 2012-04-25 Msd Kk Nouveau dérivé d'isoxazole
CN102076650A (zh) 2008-06-25 2011-05-25 第一三共株式会社 羧酸化合物
WO2010085525A1 (fr) 2009-01-23 2010-07-29 Schering Corporation Composés antidiabétiques hétérocycliques pontés et fusionnés
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
EP2440541A1 (fr) 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Nouveau composé cyclique fondu et son utilisation
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CA2779398A1 (fr) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Nouveau derive de 3-hydroxy-5-arylisoxazole
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
AU2010336225A1 (en) 2009-12-25 2012-08-16 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
CN101781268B (zh) 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体

Also Published As

Publication number Publication date
JPWO2011078371A1 (ja) 2013-05-09
GT201200217A (es) 2014-02-10
ZA201203416B (en) 2013-08-28
CN104710381A (zh) 2015-06-17
CR20120345A (es) 2012-11-01
AU2010336225A1 (en) 2012-08-16
CO6650337A2 (es) 2013-04-15
MX2012007474A (es) 2012-08-01
RU2567755C2 (ru) 2015-11-10
CL2012001722A1 (es) 2012-12-14
RU2012131840A (ru) 2014-01-27
ECSP12012056A (es) 2012-10-30
NI201200113A (es) 2012-08-13
CN102712610A (zh) 2012-10-03
KR20130004262A (ko) 2013-01-09
EA201290574A1 (ru) 2012-12-28
EP2518060A1 (fr) 2012-10-31
JP2012153726A (ja) 2012-08-16
EP2518060A4 (fr) 2014-01-08
PE20121639A1 (es) 2012-12-02
IL220616A0 (en) 2012-08-30
BR112012015612A2 (pt) 2016-03-15
PH12012501456A1 (en) 2012-10-29
JP5002077B2 (ja) 2012-08-15
SG181961A1 (en) 2012-08-30
US20120157459A1 (en) 2012-06-21
WO2011078371A1 (fr) 2011-06-30
CN102712610B (zh) 2015-03-04
HN2012001351A (es) 2015-03-23
US8476287B2 (en) 2013-07-02
CA2785674A1 (fr) 2011-06-30
NZ601408A (en) 2013-12-20

Similar Documents

Publication Publication Date Title
MA33952B1 (fr) Nouveau dérivé 3 -hydroxy- 5-arylisothiazole
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
MY152972A (en) Azabicyclo compound and salt thereof
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
NZ600837A (en) 1,3,4-oxadiazole-2-carboxamide compound
MA38540A1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
UA94424C2 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
EA201070202A1 (ru) Производное оксопиразина и гербицид
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
PH12012501643A1 (en) Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
MX2009008772A (es) Derivado piridil-triazolopirimidina o su sal, pesticida que lo contiene y proceso para su produccion.
RU2017102513A (ru) Соль гетероциклического соединения, замещенного галогеном
EA201390491A1 (ru) Производные 1,4-оксазепана
EA201200205A1 (ru) Гетероарилзамещенные циклические дионы или их производные, обладающие гербицидной активностью
CO6700877A2 (es) Derivado de difenil sulfuro y producto farmacéutico que contiene el mismo como ingrediente activo
CO5580804A2 (es) Derivados de diazepanes utiles como inhibidores de lfa
CR11875A (es) Compuestos novedosos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio (divisional 8188)
RU2013152136A (ru) Гетероциклическое производное с ароматическим 5-членным циклом, обладающее активностью антагониста рецептора npy y5
TH105904A (th) อนุพันธ์ซัลโฟนาไมด์ตัวใหม่
TH96101A (th) อนุพันธ์ของอินโดล
TH85798A (th) อนุพันธ์ของอะเซทิลีน
TH105091A (th) อะโกนิสต์ของ gpcr
TH121221A (th) สารประกอบอะซาไบไซโคลและเกลือของสิ่งนั้น
TH135032A (th) สารประกอบเฮเทโรแอริลและการใช้สารประกอบเหล่านี้